INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

LOS ANGELES, April 19, 2021

Investors who purchased the Company's securities between March 27, 2020 and March 9, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before May 17, 2021. 

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. CytoDyn touted Leronlimab as a treatment for COVID-19 to pump the Company's stock price at the same time its executives sold their shares. The Company engaged in a scheme with Iliad Research and Trading L.P. amongst others in which Iliad's principal John Fife acted as an unregistered securities dealer for CytoDyn. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about CytoDyn, investors suffered damages.